Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19199057 | 0.92 | USP2 (0.41) | TSHRUSP2CYP1A2HIF1ACYP2D6 | |
| SCHEMBL8470445 | 0.92 | TSHR (0.39) | TSHRUSP2CYP1A2HIF1ACYP2D6 | |
| SCHEMBL18535491 | 0.90 | USP2 (0.40) | TSHRUSP2CYP1A2CYP2D6CYP3A4 | |
| SCHEMBL12946062 | 0.90 | USP2 (0.40) | TSHRUSP2CYP1A2CYP2D6CYP3A4 | |
| SCHEMBL20047143 | 0.89 | TSHR (0.38) | TSHRUSP2CYP1A2HIF1ACYP2D6 | |
| SCHEMBL1375292 | 0.89 | TSHR (0.38) | TSHRUSP2CYP1A2HIF1ACYP2D6 | |
| SCHEMBL27380027 | 0.89 | TSHR (0.38) | TSHRUSP2CYP1A2HIF1ACYP2D6 | |
| SCHEMBL13890773 | 0.89 | TSHR (0.38) | TSHRUSP2CYP1A2HIF1ACYP2D6 | |
| SCHEMBL12890397 | 0.89 | NPSR1 (0.35) | TSHRUSP2CYP1A2 | |
| SCHEMBL26041077 | 0.89 | TSHR (0.38) | TSHRUSP2CYP1A2HIF1ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017136403-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| US-20170217974-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217974-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, ZC3HAV1, SLC10A1 | TSHR 2206/4885USP2 2863/4885CYP1A2 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.